{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:03:58Z","timestamp":1779098638940,"version":"3.51.4"},"reference-count":46,"publisher":"Elsevier BV","issue":"14","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vaccine.2023.02.006","type":"journal-article","created":{"date-parts":[[2023,2,11]],"date-time":"2023-02-11T15:21:38Z","timestamp":1676128898000},"page":"2320-2328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Cost-effectiveness of sub-national geographically targeted vaccination programs: A systematic review"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5831-4008","authenticated-orcid":false,"given":"Marya","family":"Getchell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ericka Joinelle","family":"Mantaring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaisin","family":"Yee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Pronyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.vaccine.2023.02.006_b0005","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1377\/hlthaff.2015.1086","article-title":"Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011\u201320","volume":"35","author":"Ozawa","year":"2016","journal-title":"Health Aff (Millwood)"},{"issue":"8","key":"10.1016\/j.vaccine.2023.02.006_b0010","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1377\/hlthaff.2020.00103","article-title":"Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011\u201330","volume":"39","author":"Sim","year":"2020","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.vaccine.2023.02.006_b0015","unstructured":"Immunization Costing Action Network (ICAN) [Internet]. Harvard University [cited April 2022]. Available from: https:\/\/dataverse.harvard.edu\/dataverse\/ICAN."},{"key":"10.1016\/j.vaccine.2023.02.006_b0020","unstructured":"EPI Costing and Financing Project (EPIC) [Internet]. 2019. Available from: http:\/\/immunizationeconomics.org\/epic."},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.02.006_b0025","doi-asserted-by":"crossref","first-page":"A93","DOI":"10.1016\/j.vaccine.2014.12.076","article-title":"What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?","volume":"33","author":"Brenzel","year":"2015","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.02.006_b0030","doi-asserted-by":"crossref","first-page":"A99","DOI":"10.1016\/j.vaccine.2014.12.037","article-title":"Costs of vaccine programs across 94 low- and middle-income countries","volume":"33","author":"Portnoy","year":"2015","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.02.006_b0035","doi-asserted-by":"crossref","first-page":"A13","DOI":"10.1016\/j.vaccine.2014.12.066","article-title":"Costs and financing of routine immunization: Approach and selected findings of a multi-country study (EPIC)","volume":"33","author":"Brenzel","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.006_b0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/1471-2458-14-67","article-title":"Updating the evidence base on the operational costs of supplementary immunization activities for current and future accelerated disease control, elimination and eradication efforts","volume":"14","author":"Gandhi","year":"2014","journal-title":"BMC Public Health"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.02.006_b0045","doi-asserted-by":"crossref","first-page":"S98","DOI":"10.1093\/infdis\/jir096","article-title":"Global eradication of measles: an epidemiologic and economic evaluation","volume":"204","author":"Levin","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2023.02.006_b0050","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1471-2458-10-253","article-title":"Health and economic impact of rotavirus vaccination in GAVI-eligible countries","volume":"10","author":"Kim","year":"2010","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2023.02.006_b0055","unstructured":"Planning and Implementing High-Quality Supplementary Immunization Activities for Injectable Vaccines Using an Example of Measles and Rubella Vaccines: field guide. [Internet]. World Health Organization. 2016. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241511254."},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.006_b0060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12916-020-01687-7","article-title":"Seasonal influenza vaccination in Kenya: an economic evaluation using dynamic transmission modelling","volume":"18","author":"Dawa","year":"2020","journal-title":"BMC Med"},{"issue":"5","key":"10.1016\/j.vaccine.2023.02.006_b0065","doi-asserted-by":"crossref","first-page":"e0004661","DOI":"10.1371\/journal.pntd.0004661","article-title":"Projected Impact of Dengue Vaccination in Yucatan, Mexico","volume":"10","author":"Hladish","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"45","key":"10.1016\/j.vaccine.2023.02.006_b0070","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1016\/j.vaccine.2017.09.038","article-title":"Assessing the cost-effectiveness of different measles vaccination strategies for children in the Democratic Republic of Congo","volume":"35","author":"Doshi","year":"2017","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2023.02.006_b0075","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S1473-3099(18)30804-1","article-title":"Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study","volume":"19","author":"Bilcke","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2023.02.006_b0080","doi-asserted-by":"crossref","first-page":"e0008304","DOI":"10.1371\/journal.pntd.0008304","article-title":"Eliminating yellow fever epidemics in Africa: Vaccine demand forecast and impact modelling","volume":"14","author":"Jean","year":"2020","journal-title":"PLoS Negl Trop Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.006_b0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12916-021-02157-4","article-title":"Effect of evidence updates on key determinants of measles vaccination impact: a DynaMICE modelling study in ten high-burden countries","volume":"19","author":"Fu","year":"2021","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.006_b0090","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00019053-200826010-00003","article-title":"Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies","volume":"26","author":"Anonychuk","year":"2008","journal-title":"Pharmacoeconomics"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2023.02.006_b0095","doi-asserted-by":"crossref","first-page":"C55","DOI":"10.1016\/j.vaccine.2015.04.028","article-title":"Typhoid fever vaccination strategies","volume":"33","author":"Date","year":"2015","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.02.006_b0100","doi-asserted-by":"crossref","first-page":"A184","DOI":"10.1016\/j.vaccine.2019.07.082","article-title":"Oral cholera vaccine delivery strategy in India: Routine or campaign?-A scoping review","volume":"38","author":"Ray","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.006_b0105","unstructured":"Strings attached: CADTH database search filters [Internet]. 2021 [cited December 1, 2021]. Available from: https:\/\/www.cadth.ca\/cadth-search-filters-database."},{"key":"10.1016\/j.vaccine.2023.02.006_b0110","unstructured":"Critical Appraisal Skills Programme (CASP) Economic Evaluation Checklist [Internet]. 20Available from: https:\/\/casp-uk.net\/casp-tools-checklists\/."},{"key":"10.1016\/j.vaccine.2023.02.006_b0115","unstructured":"World Bank Country Classification by Income [Internet]. World Bank. 2022. Available from: https:\/\/datahelpdesk.worldbank.org\/knowledgebase\/articles\/906519-world-bank-country-and-lending-groups."},{"issue":"10","key":"10.1016\/j.vaccine.2023.02.006_b0120","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40273-020-00942-2","article-title":"Perspective and Costing in Cost-Effectiveness Analysis, 1974\u20132018","volume":"38","author":"Kim","year":"2020","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"10.1016\/j.vaccine.2023.02.006_b0125","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/hec.1148","article-title":"A taxonomy of model structures for economic evaluation of health technologies","volume":"15","author":"Brennan","year":"2006","journal-title":"Health Econ"},{"issue":"11","key":"10.1016\/j.vaccine.2023.02.006_b0130","doi-asserted-by":"crossref","first-page":"e1002181","DOI":"10.1371\/journal.pmed.1002181","article-title":"The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study","volume":"13","author":"Flasche","year":"2016","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.vaccine.2023.02.006_b0135","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jval.2015.02.004","article-title":"Public Health Impact and Cost-Effectiveness of Hepatitis A Vaccination in the United States: A Disease Transmission Dynamic Modeling Approach","volume":"18","author":"Dhankhar","year":"2015","journal-title":"Value Health"},{"issue":"13","key":"10.1016\/j.vaccine.2023.02.006_b0140","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.vaccine.2020.02.018","article-title":"Japanese encephalitis vaccination in the Philippines: A cost-effectiveness analysis comparing alternative delivery strategies","volume":"38","author":"Vodicka","year":"2020","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2023.02.006_b0145","doi-asserted-by":"crossref","first-page":"e1003003","DOI":"10.1371\/journal.pmed.1003003","article-title":"The projected impact of geographic targeting of oral cholera vaccination in sub-Saharan Africa: A modeling study","volume":"16","author":"Lee","year":"2019","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2023.02.006_b0150","unstructured":"Measles and rubella strategic framework 2021-2030 [Internet]. World Health Organization. 2020. Available from: https:\/\/www.who.int\/publications\/i\/item\/measles-and-rubella-strategic-framework-2021-2030."},{"issue":"5","key":"10.1016\/j.vaccine.2023.02.006_b0155","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s40273-017-0487-3","article-title":"The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling","volume":"35","author":"Shafie","year":"2017","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.006_b0160","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1300\/J371v15n01_05","article-title":"A cost-effectiveness analysis of strategies for controlling Japanese encephalitis in Andhra Pradesh, India","volume":"15","author":"Suraratdecha","year":"2006","journal-title":"Journal of Pharmaceutical Finance, Economics and Policy"},{"key":"10.1016\/j.vaccine.2023.02.006_b0165","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1093\/infdis\/jix598","article-title":"Comparison of Strategies and Incidence Thresholds for VI Conjugate Vaccines Against Typhoid Fever: A Cost-effectiveness Modeling Study","volume":"218","author":"Lo","year":"2018","journal-title":"J Infect Dis"},{"issue":"41","key":"10.1016\/j.vaccine.2023.02.006_b0170","doi-asserted-by":"crossref","first-page":"6039","DOI":"10.1016\/j.vaccine.2019.08.050","article-title":"Optimization of frequency and targeting of measles supplemental immunization activities in Nigeria: A cost-effectiveness analysis","volume":"37","author":"Zimmermann","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.006_b0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3402\/gha.v6i0.20056","article-title":"Supplementary immunization activities (SIAs) in South Africa: comprehensive economic evaluation of an integrated child health delivery platform","volume":"6","author":"Verguet","year":"2013","journal-title":"Glob Health Action"},{"issue":"2","key":"10.1016\/j.vaccine.2023.02.006_b0180","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/aje\/kwt236","article-title":"Reaching hard-to-reach individuals: Nonselective versus targeted outbreak response vaccination for measles","volume":"179","author":"Minetti","year":"2014","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2023.02.006_b0185","doi-asserted-by":"crossref","unstructured":"Anderson JD, Muhib F, Rheingans R, Wierzba T. Heterogeneity in potential impact and cost-effectiveness of ETEC and Shigella vaccination in four sub-Saharan African countries. Vaccine: X. 2019;3.","DOI":"10.1016\/j.jvacx.2019.100043"},{"issue":"5","key":"10.1016\/j.vaccine.2023.02.006_b0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232941","article-title":"Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and costeffectiveness of vaccination in Nigeria","volume":"15","author":"Anderson","year":"2020","journal-title":"PLoS One"},{"issue":"S1","key":"10.1016\/j.vaccine.2023.02.006_b0195","doi-asserted-by":"crossref","first-page":"A140","DOI":"10.1016\/j.vaccine.2014.05.073","article-title":"Estimated impact and cost-effectiveness of rotavirus vaccination in India: Effects of geographic and economic disparities","volume":"32","author":"Rheingans","year":"2014","journal-title":"Vaccine"},{"issue":"51","key":"10.1016\/j.vaccine.2023.02.006_b0200","doi-asserted-by":"crossref","first-page":"7780","DOI":"10.1016\/j.vaccine.2018.02.008","article-title":"Effects of geographic and economic heterogeneity on the burden of rotavirus diarrhea and the impact and cost-effectiveness of vaccination in Pakistan","volume":"36","author":"Rheingans","year":"2018","journal-title":"Vaccine"},{"issue":"51","key":"10.1016\/j.vaccine.2023.02.006_b0205","doi-asserted-by":"crossref","first-page":"7868","DOI":"10.1016\/j.vaccine.2018.02.009","article-title":"Effects of geographic and economic heterogeneity on rotavirus diarrhea burden and vaccination impact and cost-effectiveness in the Lao People's Democratic Republic","volume":"36","author":"Rheingans","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.02.006_b0210","unstructured":"Immunization Agenda 2030: A Global Strategy to Leave No One Behind [Internet]. World Health Organization. 2020. Available from: https:\/\/www.who.int\/teams\/immunization-vaccines-and-biologicals\/strategies\/ia2030."},{"issue":"12","key":"10.1016\/j.vaccine.2023.02.006_b0215","doi-asserted-by":"crossref","first-page":"e038282","DOI":"10.1136\/bmjopen-2020-038282","article-title":"Digital health for real-time monitoring of a national immunisation campaign in Indonesia: a large-scale effectiveness evaluation","volume":"10","author":"Jusril","year":"2020","journal-title":"BMJ Open"},{"issue":"9759","key":"10.1016\/j.vaccine.2023.02.006_b0220","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0140-6736(10)60810-0","article-title":"Measuring impact in the Millennium Development Goal era and beyond: a new approach to large-scale effectiveness evaluations","volume":"377","author":"Victora","year":"2011","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.vaccine.2023.02.006_b0225","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1097\/01.inf.0000091295.53969.6a","article-title":"Regional variation in the cost effectiveness of childhood hepatitis A immunization","volume":"22","author":"Jacobs","year":"2003","journal-title":"Pediatr Infect Dis J"},{"issue":"25\u201326","key":"10.1016\/j.vaccine.2023.02.006_b0230","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1016\/j.vaccine.2004.02.042","article-title":"Economic analysis of the 1996\u20131997 mass measles immunization campaigns in South Africa","volume":"22","author":"Uzicanin","year":"2004","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:23:58Z","timestamp":1759404238000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23001329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":46,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0264410X23001329"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.006","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness of sub-national geographically targeted vaccination programs: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}